Drug intelligence / Profile preview

mezlocillin + netilmicin

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Mezlocillin + netilmicin is a fixed-dose combination of two antibiotics used primarily for the prophylaxis and treatment of serious bacterial infections, especially in surgical settings such as cardiac pacemaker implantation[1][2]. Mezlocillin is an extended-spectrum penicillin (beta-lactam antibiotic) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis[3][8][10]. Netilmicin is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of bacteria, interfering with protein synthesis by causing misreading of mRNA and production of nonfunctional or toxic peptides[4][6]. The combination provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. This synergistic effect makes it particularly useful for preventing infections caused by methicillin-resistant staphylococci and other difficult-to-treat organisms in high-risk surgical procedures[1][5].

Other names
mezlocillin-netilmicin combinationmezlocillin and netilmicin
02

Targets

PBP2 (Penicillin-binding protein 2)30S A-site (Bacterial ribosomal 30S A-site)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)

Beyond the preview

Go deeper on mezlocillin + netilmicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mezlocillin + netilmicin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call